Anavex Life Sciences Corp. (AVXL)
| Market Cap | 787.25M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -43.22M |
| Shares Out | 77.41M |
| EPS (ttm) | -0.58 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,228,203 |
| Open | 10.56 |
| Previous Close | 10.45 |
| Day's Range | 9.78 - 10.66 |
| 52-Week Range | 7.13 - 31.50 |
| Beta | 0.92 |
| Analysts | Buy |
| Price Target | 36.04 (+254.4%) |
| Earnings Date | Aug 11, 2022 |
About AVXL
Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patients with Rett syndrome; Phase II clinical trial for the treatment of Parkinson's disease; and preclinical clinical trials to treat epilepsy, infantile spasms, Fragile X syndrome, Angelman syndrome, multip... [Read more...]
Financial Performance
Financial StatementsAnalyst Forecast
According to 11 analysts, the average rating for AVXL stock is "Buy." The 12-month stock price forecast is 36.04, which is an increase of 254.38% from the latest price.
News
How Much Upside is Left in Anavex Life Sciences (AVXL)? Wall Street Analysts Think 286%
The average of price targets set by Wall Street analysts indicates a potential upside of 286.4% in Anavex Life Sciences (AVXL). While the effectiveness of this highly sought-after metric is questionable...
Anavex's Publication Supports Clinical Biomarker for ANAVEX®2-73 in Fragile X Syndrome
Publication Demonstrates the Feasibility to Use Blood Biomarkers to Monitor Response to ANAVEX®2-73 (blarcamesine) in Clinical Trials of Fragile X Syndrome (Major Cause of Autism) Publication Demonstrat...
Does Anavex Life Sciences (AVXL) Have the Potential to Rally 265% as Wall Street Analysts Expect?
The average of price targets set by Wall Street analysts indicates a potential upside of 265% in Anavex Life Sciences (AVXL). While the effectiveness of this highly sought-after metric is questionable, ...
Anavex Life Sciences to Present at the H. C. Wainwright Global Investment Conference 2022
NEW YORK, May 19, 2022 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for th...
Anavex Life Sciences Provides Business Update and Reports Fiscal 2022 Second Quarter Financial Results
Company to host a webcast today at 4:30 p.m. Eastern Time
(AVXL) News: Did You Lose Money on Anavex Life Sciences Corp. Investment? Contact Johnson Fistel Regarding Class Acti...
San Diego, California--(Newsfile Corp. - May 6, 2022) - Shareholder rights law firm Johnson Fistel, LLP is investigating potential violations of federal securities laws by Anavex Life Sciences Corp. ("A...
Anavex Life Sciences to Announce Fiscal 2022 Second Quarter Financial Results on Tuesday May 10, 2022
Webcast and Conference Call To be Held Tuesday May 10, 2022, 4:30 pm ET Webcast and Conference Call To be Held Tuesday May 10, 2022, 4:30 pm ET
Anavex Life Sciences Announces Presentations at the IRSF Rett Syndrome Scientific Meeting
Presentations cover the Psychometric Evaluation of the Rett Syndrome Behaviour Questionnaire (RSBQ) and the Burden of Illness (BOI) Study in Rett Syndrome Presentations cover the Psychometric Evaluation...
Anavex Life Sciences Invited to Present at the B. Riley Securities' 2022 Virtual Neuro & Ophthalmology Conference
NEW YORK, April 26, 2022 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for ...
Anavex Life Sciences to Present at the Needham Virtual Healthcare Conference
NEW YORK, April 07, 2022 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for ...
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Anavex Life Sciences Corp. Investors With Losses to Inquire About Securiti...
NEW YORK--(BUSINESS WIRE)-- #ANAVEX273--WHY: Rosen Law Firm, a global investor rights law firm, continues its investigation of potential securities claims on behalf of shareholders of Anavex Life Scienc...
ROSEN, A TOP RANKED LAW FIRM, Encourages Anavex Life Sciences Corp. Investors to Inquire About Securities Class Actio...
New York, New York--(Newsfile Corp. - April 1, 2022) - WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Anavex Li...
Anavex Life Sciences to Participate in the Cantor Virtual Rare Orphan Disease Summit
NEW YORK, March 28, 2022 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for ...
Anavex Life Sciences Corp. Investigated by Block & Leviton For Potential Securities Law Violations; Investors Who Hav...
Boston, Massachusetts--(Newsfile Corp. - March 21, 2022) - Block & Leviton is investigating Anavex Life Sciences Corp. (NASDAQ: AVXL) for potential securities law violations. Investors who have lost mon...
ROSEN, A LEADING LAW FIRM, Encourages Anavex Life Sciences Corp. Investors to Inquire About Securities Class Action I...
NEW YORK , March 15, 2022 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Anavex Life Sciences C...
Anavex Life Sciences Highlights Biomarker Data From Parkinson's Disease Dementia At International Conference
Anavex Life Sciences Corp (NASDAQ: AVXL) has announced the presentation of Phase 2 clinical biomarker data from the ANAVEX2-73-PDD-001 Parkinson's Disease Dementia (PDD) study at the AD/PD 2022 Internat...
Anavex Life Sciences to Participate in the Annual Needham Virtual Neuroscience Forum
NEW YORK, March 09, 2022 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for ...
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Continues Its Investigation of Anavex Life Sciences...
LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, continues its investigation on behalf of Anavex Life Sciences Corp. (“Anavex” or the “C...
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Anavex Life Sciences Corp. Investors to Inquire About Securities Class...
NEW YORK, March 7, 2022 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, continues its investigation of potential securities claims on behalf of shareholders of Anavex Life Scienc...
INVESTOR ALERT: Law Offices of Howard G. Smith Continues Its Investigation of Anavex Life Sciences Corp. (AVXL) on Be...
BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith continues its investigation on behalf of Anavex Life Sciences Corp. (“Anavex” or the “Company”) (NASDAQ: AVXL) on behalf of investors conce...
The Law Offices of Frank R. Cruz Continues Its Investigation of Anavex Life Sciences Corp. (AVXL) on Behalf of Investors
LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz continues its investigation of Anavex Life Sciences Corp. (“Anavex” or the “Company”) (NASDAQ: AVXL) on behalf of investors concerning the ...
Anavex Life Sciences Announces Change of Auditor to Grant Thornton LLP
NEW YORK, March 04, 2022 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for ...
ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Anavex Life Sciences Corp. Investors with Losses to Inquire About Sec...
New York, New York--(Newsfile Corp. - February 22, 2022) - WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Anave...
ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Anavex Life Sciences Corp. Investors to Inquire About Securitie...
NEW YORK, Feb. 18, 2022 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Anavex Life Sciences Cor...
ROSEN, TRUSTED AND TOP RANKED INVESTOR COUNSEL, Encourages Anavex Life Sciences Corp. Investors to Inquire About Secu...
New York, New York--(Newsfile Corp. - February 16, 2022) - WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Anave...